04th week of 2011 patent applcation highlights part 47 |
Patent application number | Title | Published |
20110021440 | APOPTOTIC PATHWAY TARGETING FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to methods of treating cancer. The invention further relates to a method of treating cancer by exploiting apoptotic pathways. The invention particularly relates to regulation of apoptotic pathways in cancerous cells, to metastasis of cancer cells, and to methods of preventing cancer metastasis. | 2011-01-27 |
20110021441 | CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER - The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor. | 2011-01-27 |
20110021442 | CELL PREAMBLE RUNX3 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTICANCER COMPOSITIONS INCLUDING THE SAME - The present invention discloses cell permeable RUNX3 recombinant proteins where a Macromolecule Transduction Domain (MTD) is fused to a tumor and metastasis suppressor RUNX3. Also disclosed are polynucleotides encoding the cell permeable RUNX3 recombinant proteins, an expression vector containing the cell permeable RUNX3 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable RUNX3 recombinant protein as an effective ingredient. The cell permeable RUNX3 recombinant proteins of the present invention can induce the reactivation of TGF-β signal transduction pathway which causes cell cycle arrest by efficiently introducing a tumor and metastasis suppressor RUNX3 into a cell. Therefore, the cell permeable RUNX3 recombinant proteins of the present invention can be effectively used as an anticancer agent capable of preventing cancer growth and metastasis by suppressing the proliferation, differentiation, and migration of cancer cells. | 2011-01-27 |
20110021443 | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES - Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof. | 2011-01-27 |
20110021444 | COMPOSITIONS FOR CONTROLLING HAIR GROWTH - FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed. | 2011-01-27 |
20110021446 | COMPOSITIONS AND METHODS FOR FEEDING POULTRY - Feed supplements for poultry raised using a rapid growth regimen are disclosed herein. The supplements include D-ribose in an amount effective to improve the resistance to cardiomyopathy in the poultry. Methods for feeding poultry are also disclosed herein. | 2011-01-27 |
20110021447 | ACNE TREATMENT COMPOSITION AND METHODS FOR USING - An acne treatment composition is provided according to the present invention. The acne treatment composition includes an effective amount of an anti-acne component to provide anti-acne properties to skin tissue, an effective amount of a skin bounding polymer component to provide sustained release of the anti-acne component over a prolonged period of time after application of the acne treatment composition to skin tissue, and water. A method of using an acne treatment composition is provided. | 2011-01-27 |
20110021448 | Inhibitors for the Soluble Epoxide Hydrolase - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. | 2011-01-27 |
20110021449 | MACROLIDES AND USES OF MACROLIDES - Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or. cancer in animals and humans. | 2011-01-27 |
20110021450 | MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXAZINE COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTOZOAL DISEASE - Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient. | 2011-01-27 |
20110021451 | LIPID TUMOUR PROFILE - We describe a method of generating a classification model capable of distinguishing between two biological states, the method comprising the steps of: (a) providing a training dataset, X, comprising concentrations of a plurality of lipids in a biological sample in a first state and a biological sample in a second state; (b) subjecting the training dataset X to Principal Components Analysis (PCA), in which the PCA analysis generates a transformation matrix, C, and a transformed dataset, Y | 2011-01-27 |
20110021452 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS - The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said preparation is useful as a chemotherapeutic agent for cancers. | 2011-01-27 |
20110021453 | Methods and compositions for providing cardiac protection - The invention provides a method of treating a cardiac disease by administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent, such as, for instance a β-blocker. In some embodiments, the AC5 inhibiting compound is 9-β-D-arabinofuranosyladenine (AraAde). The compound may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered parenterally. The cardiac disease may be, for instance, myocardial infarction (MI) or heart failure (HF). The compound capable of inhibiting AC5 may be administered alone or in conjunction with one or more other active agents. Likewise, the invention provides a method of treating a heart attack, a method of inhibiting myocardial apoptosis, and a method of treating heart failure by administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient in the same manner. | 2011-01-27 |
20110021454 | MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS - Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4′-C-substituted β-D- and β-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided. | 2011-01-27 |
20110021455 | STERILISED SUCRALFATE GEL - The present invention relates to an autoclave-sterilized gel comprising sucralfate and at least 15% by weight of a humectant, relative to the total weight of gel, and having a pH of greater than or equal to 6, more particularly for use in a skin healing treatment by topical application. | 2011-01-27 |
20110021456 | Sweetening compositions and processes for preparing them - The invention relates to sweetening compositions containing from about 16% to about 75% mogroside V and from about 30% to about 95% total terpene glycosides on a dry weight basis, and wherein a filtered (0.2 μm) solution of the composition in water having a solids content of 1% w/v has an absorbance at 420 nm of about 0.55 or below. The invention also relates to methods of preparing such compositions. | 2011-01-27 |
20110021457 | PHARMACEUTICAL COMPOSITIONS COMPRISING MODIFIED FUCANS AND METHODS RELATING THERETO - Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases. | 2011-01-27 |
20110021458 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN INCLUSION COMPLEX FORMED BY DISULFIRAM AND A CYCLODEXTRINE, WHICH CAN BE USED IN THE TREATMENT OF ALCOHOL AND COCAINE DEPENDENCE - The invention relates to a novel pharmaceutical composition containing a complex of disulfiram (DSF) with a cyclodextrin (CD), to the method for obtaining same and to the use thereof in the treatment of alcohol and cocaine dependence. | 2011-01-27 |
20110021459 | DUTPASE INHIBITORS - Deoxyuridine derivatives of the formula | 2011-01-27 |
20110021460 | SELECTIVE HYDROSILYLATION METHOD AND PRODUCT - An asymmetric siloxane is made by reacting a silicone having the formula M | 2011-01-27 |
20110021461 | COMBINATIONS TO IMPROVE ANIMAL HEALTH AND PERFORMANCE - The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof. | 2011-01-27 |
20110021462 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF - This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. | 2011-01-27 |
20110021463 | Method of Treating Citrus Plants to Reduce Bacterial Infections - A method of treating a citrus plant is provided to reduce the incidence of one or more insect-vectored bacterial infections such as citrus greening. The method comprises the step of applying a treatment composition one or more times to the plant, wherein the treatment composition comprises an effective amount of aluminum tris(O-ethyl phosphonate). | 2011-01-27 |
20110021464 | METHODS OF TREATING VIRAL INFECTIONS - The present invention provides methods of treating human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, including administering a compound described in the invention in an amount effective treat the HIV and/or HBV infection and at least substantially inhibit the development of resistance to said antiviral compounds in the subject. Pharmaceutical compositions are also provided. | 2011-01-27 |
20110021465 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 2011-01-27 |
20110021466 | USE OF EPICATECHIN AND DERIVATIVES AND SALTS THEREOF FOR CARDIAC PROTECTION OF ISCHEMIC MYOCARDIUM AND TO AMELIORATE ADVERSE CARDIAC REMODELING - The disclosure provides a method of reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof, wherein the subject is a human or a veterinary animal. Additionally the disclosure provides a method of treating subarachnoid hemorrhage or atrial fibrillation or of enhancing or preserving migration, seeding, proliferation, differentiation and/or survival of stem cells in injured heart tissue comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof. The effects of epicatechin administration are sustained over time. | 2011-01-27 |
20110021467 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA - The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt. | 2011-01-27 |
20110021468 | TREATMENT OF CARDIOVASCULAR DISEASE WITH SALICYLATES - This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate. | 2011-01-27 |
20110021469 | BACLOFEN SOLUTION FOR LOW-VOLUME THERAPEUTIC DELIVERY - A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity. | 2011-01-27 |
20110021470 | METHODS FOR TREATING CANCER COMPRISING THE ADMINISTRATION OF A VITAMIN D COMPOUND AND AN ADDITIONAL THERAPEUTIC AGENT, AND COMPOSITIONS CONTAINING THE SAME - Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid, e.g., corticosteroid or more specifically, a glucocorticoid. | 2011-01-27 |
20110021471 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION - This document relates to methods and materials for reducing Aβ42 levels, reducing Aβ aggregation, or reducing both Aβ42 levels and Aβ aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5β-cholanic acid) to reduce Aβ42 levels and to reduce Aβ aggregation in mammals. | 2011-01-27 |
20110021472 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE - The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the chemical formula I, where R | 2011-01-27 |
20110021473 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV - The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors. | 2011-01-27 |
20110021474 | Ecdysterone Compounds - An ecdysterone compound is described. An ecdysterone compound may include ecdysterone and decanoic acid. An ecdysterone compound may further include ecdysterone and isobutyric acid. An ecdysterone compound may comprise a physiologically active salt or ester of ecdysterone. An ecdysterone compound may further comprise a physiologically active salt or ester of decanoic acid. Alternatively, an ecdysterone compound may include a physiologically active salt or ester of isobutyric acid. | 2011-01-27 |
20110021475 | Compositions And Methods for Treatment Of Fibrosis - Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided. | 2011-01-27 |
20110021476 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 2011-01-27 |
20110021477 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2011-01-27 |
20110021478 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS - Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases. | 2011-01-27 |
20110021479 | PYRROLOPYRIMIDINECARBOXAMIDES - The compounds of Formula (I), | 2011-01-27 |
20110021480 | 17-beta HSD1 and STS Inhibitors - Substituted steroid compounds which represent selective inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17β-estradiol concentration. | 2011-01-27 |
20110021481 | Novel Compounds and Methods for Their Production - The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine. | 2011-01-27 |
20110021482 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents - A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: | 2011-01-27 |
20110021483 | Platinum (IV) Complexes - Provided are nitroplatinum(IV) complexes containing a bidentate dicarboxylate ligand (e.g., oxalate) which maybe useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages. | 2011-01-27 |
20110021484 | Gallium compounds and methods of use to treat inflammatory bowel disease - Provided are formulations and methods for treating inflammatory bowel disease, including Crohn's disease, ulcerative colitis, and Johne's disease. The formulations provided comprise pharmaceutically acceptable gallium compounds; the methods provided comprise means of using such formulations in the treatment of inflammatory bowel disease and closely related disorders. | 2011-01-27 |
20110021485 | INDOLE DERIVATIVES AND THEIR METAL CONJUGATES AND USES THEREOF - Provided are compounds which are indole derivatives, as well as pharmaceutical compositions containing the compounds. Also provided are methods of using the indole compounds for preventing or treating a disease, or a condition that predisposes to a disease, wherein the disease or condition is associated with activation of the serine/threonine kinase B (Akt) in an animal. The method comprises administering to the animal a preventive or treatment effective amount of the indole compound. Further provided is a method for increasing apoptosis of an animal cell comprising contacting the cell with the indole compound. | 2011-01-27 |
20110021486 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 2011-01-27 |
20110021487 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE - The present application relates to novel cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders. | 2011-01-27 |
20110021488 | New Compounds - The present invention relates to compounds of general formula I | 2011-01-27 |
20110021489 | SUBSTITUTED PIPERIDINES - The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders. | 2011-01-27 |
20110021490 | Chromene compounds, a process for their preparationand pharmaceutical compositions containing them - The invention relates to compounds of formula (I): | 2011-01-27 |
20110021491 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO - New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): | 2011-01-27 |
20110021492 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2011-01-27 |
20110021493 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF - This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer. | 2011-01-27 |
20110021494 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS - The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. | 2011-01-27 |
20110021495 | QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2011-01-27 |
20110021496 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS - Thienopyrimidines of formula (I) wherein W and R | 2011-01-27 |
20110021497 | AMINO TRIAZOLES AS PI3K INHIBITORS - The invention relates to compounds of formula (I) | 2011-01-27 |
20110021498 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY - Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R | 2011-01-27 |
20110021499 | URETHRAL SUPPOSITORIES FOR OVERACTIVE BLADDER - Urethral suppositories containing a mixed-activity anti-cholinergic drug and methods of use for treatment of over-active bladder are provided. Buffering drugs to pH near their pKas can result in a desired proportion of uncharged drug and can enhance absorption of the agents into urethral tissues. | 2011-01-27 |
20110021500 | NOVEL COMPOUNDS - The present invention relates to new CGRP-antagonists of general formula I | 2011-01-27 |
20110021501 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES - The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, | 2011-01-27 |
20110021502 | USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION - The invention discloses the use of cholinesterase inhibitors in treating vascular depression. | 2011-01-27 |
20110021503 | USE AND COMPOSITION FOR TREATING DEMENTIA - There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described. | 2011-01-27 |
20110021504 | POLYMORPHIC FORM D OF BAZEDOXIFENE ACETATE AND METHODS OF PREPARING SAME - The present disclosure relates to polymorphic Form D of bazedoxifene acetate, pharmaceutical compositions and methods of treatment using the same, and methods of preparing the same. | 2011-01-27 |
20110021505 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain - The present invention relates to the use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides of the formula I, | 2011-01-27 |
20110021506 | ANTHELMINTIC AGENTS AND THEIR USE - This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments. | 2011-01-27 |
20110021507 | INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN - The present invention provides methods, compositions and kits for preventing, inhibiting, reducing and reversing weight gain induced by antipsychotic medications, for example olanzapine and clozapine, by co-administration of an M | 2011-01-27 |
20110021508 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement - The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition. | 2011-01-27 |
20110021509 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: | 2011-01-27 |
20110021510 | METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. | 2011-01-27 |
20110021511 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM - The invention relates to compounds of general formula 1 | 2011-01-27 |
20110021512 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula Ik, Im | 2011-01-27 |
20110021513 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE - The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase. | 2011-01-27 |
20110021514 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2011-01-27 |
20110021515 | DIHYROFUROPYRMINDINE COMPOUNDS - The present invention provides mTOR inhibitors of the formula | 2011-01-27 |
20110021516 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS - The present invention is directed to compounds of the formula (I): (wherein variables A | 2011-01-27 |
20110021517 | ANTITUMOR COMBINATION COMPRISING A MORPHOLINYL ANTHRACYCLINE DERIVATIVE AND DEMETHYLATING AGENTS - The present invention provides a combination of a morpholinyl anthracycline derivative, in particular a methoxy morpholino doxorubicin derivative, or a pharmaceutically acceptable salt thereof, and a demethylating agent, having an antineo-plastic effect. Also provided is the use of the said combinations in the treatment or prevention of metastasis, in the treatment of tumors, as well for reversing the resistance in cells resistant to such a methoxy morpholino doxorubicin derivative. | 2011-01-27 |
20110021518 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE - This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer. | 2011-01-27 |
20110021519 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2011-01-27 |
20110021520 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to novel heterocyclic compounds of the formula | 2011-01-27 |
20110021521 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 2011-01-27 |
20110021522 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 - The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases. | 2011-01-27 |
20110021523 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2011-01-27 |
20110021524 | COMPOSITIONS AND METHODS FOR TREATING CANCERS - This invention provides a combination of ATP-competitive BCR-ABL inhibitor and a non-ATP competitive BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with BCR-ABL. | 2011-01-27 |
20110021525 | P70S6 Kinase Modulators and Method of Use - The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. | 2011-01-27 |
20110021526 | Pharmaceutical Composition for Treatment of Diabetic Complications - A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose reductase, one of the chief causative factors of diabetic complications. Also provided are methods of diabetic wound healing. Compositions for treating diabetic complications, such as diabetic wounds, are disclosed. The present invention includes employing a topical formulation of a beta-blocker, having substantially no antibacterial activity, to improve the process of diabetic wound healing. The present invention also involves increasing the rate of collagen accumulation of the healing epithelialized tissue in the wound of a diabetic individual. | 2011-01-27 |
20110021527 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2011-01-27 |
20110021528 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 2011-01-27 |
20110021529 | P53 ACTIVATING COMPOUNDS - The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions (involving sirtuin function). | 2011-01-27 |
20110021530 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS - Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R | 2011-01-27 |
20110021531 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH - The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease. | 2011-01-27 |
20110021532 | NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE - Substituted heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I). | 2011-01-27 |
20110021533 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION - The present invention provides cysteine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction. | 2011-01-27 |
20110021534 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them. | 2011-01-27 |
20110021535 | Trazodone Composition for Once a Day Administration - The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. | 2011-01-27 |
20110021536 | Crystalline Forms and Two Solvated Forms of 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quino- lin-2(1H)-one Lactic Acid Salts - Crystalline forms or polymorphs of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same. | 2011-01-27 |
20110021537 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS - The present invention relates to compounds of the formula I, | 2011-01-27 |
20110021538 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR - The present invention relates to processes for preparing pyrazole derivatives of Formula (I) and salts and pharmaceutical compositions of the salts thereof, useful as modulators of 5-HT | 2011-01-27 |
20110021539 | Pyrazinylpyrazoles - Pyrazin-2-ylpyrazoles are described, as is the use thereof as insecticides and/or parasiticides. | 2011-01-27 |
20110021540 | Bis-(Sulfonylamino) Derivatives in Therapy 066 - The invention provides compounds of formula wherein R | 2011-01-27 |